HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2010 | 110947 | 134538 | 82.5% | |
| HF 4 | 2011 | 114608 | 139581 | 82.1% | |
| HF 4 | 2012 | 128996 | 153868 | 83.8% | |
| HF 4 | 2013 | 138646 | 159898 | 86.7% | |
| HF004 | 2014 | 82465 | 89636 | 92.0% | |
| HF004 | 2015 | 94528 | 102203 | 92.5% | |
| HF004 | 2016 | 106862 | 115573 | 92.5% | |
| HF004 | 2017 | 109760 | 118657 | 92.5% | |
| HF004 | 2018 | 121418 | 131509 | 92.3% | |
| HF004 | 2019 | 140922 | 153454 | 91.8% | |
| HF004 | 2020 | 154618 | 169200 | 91.4% | |
| HF004 | 2021 | 227630 | 254277 | 89.5% | |
| HF004 | 2022 | 214494 | 226425 | 94.7% | |
| HF004 | 2023 | 250162 | 260661 | 96.0% |
